One of the most promising new approaches currently in clinical trials for postmenopausal osteoporosis is the promotion of bone formation by antibodies directed against the Wnt inhibitor, sclerostin. A new study by Wehmeyer and colleagues suggests that this approach might have a pro-inflammatory effect in patients with tumour necrosis factor (TNF)-dependent rheumatoid arthritis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wehmeyer, C. et al. Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction. Sci. Transl Med. 8, 330ra35 (2016).
Chen, X. X. et al. Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis. Ann. Rheum. Dis. 72, 1732–1736 (2013).
McClung, M. R. et al. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 370, 412–420 (2014).
Appelman-Dijkstra, N. M. & Papapoulos, S. E. Sclerostin inhibition in the management of osteoporosis. Calcif. Tissue Int. 98, 370–380 (2016).
Appel, H. et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 60, 3257–3262 (2009).
Heiland, G. R. et al. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann. Rheum. Dis. 69, 2152–2159 (2010).
Vincent, C. et al. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFα induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J. Bone Miner. Res. 24, 1434–1449 (2009).
Chan, B. Y. et al. Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis. Osteoarthritis Cartilage 19, 874–885 (2011).
Diarra, D. et al. Dickkopf-1 is a master regulator of joint remodeling. Nat. Med. 13, 156–163 (2007).
Walsh, N. C. et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J. Bone Miner. Res. 24, 1572–1585 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Sims, N. Does anti-sclerostin therapy promote inflammation in rheumatoid arthritis?. Nat Rev Endocrinol 12, 314–316 (2016). https://doi.org/10.1038/nrendo.2016.59
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2016.59
